FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955480419> ?p ?o ?g. }

• W2955480419 endingPage "306" @default.
• W2955480419 startingPage "301" @default.
• W2955480419 abstract "Squamous cell carcinoma of the anal canal (SCCA) presents a rising incidence in the United States. Standard of care for locally advanced disease is comprised of infusional 5-fluorouracil with mitomycin C or cisplatin concurrent with radiation therapy (RT). We designed this trial to evaluate the efficacy and safety of a more convenient regimen composed of capecitabine and oxaliplatin.This was a single-arm, phase II trial, with treatment-naive stage II to IIIB (TX,1-4NxM0) SCCA patients. The regimen was composed of capecitabine (825 mg/m2 twice per day for 5 days) and oxaliplatin (50 mg/m2 weekly) during weeks 1 through 6, concurrent with RT (XELOX-XRT; group 1). After the first 11 patients, the study was amended to omit chemotherapy during the third and sixth weeks (group 2). The primary objective was 3-year time to treatment failure (TTF) and safety. Secondary objectives were complete response (CR) rate, locoregional control, colostomy-free survival (CFS), and overall survival (OS).Twenty patients were enrolled. Seven patients of group 1 (63%) developed Grade 3 toxicity, which reduced to 22% in Group 2. No Grade 4 toxicities were noted. The median RT dose was 55 Gy. CR occurred in 100% of the 19 patients evaluable for response at 12 to 14 weeks. After a median follow-up of 47.6 months, 2 patients had local recurrence and 1 had distant recurrence. Three-year TTF was 90.0%, with similar rates between groups 1 and 2 (respectively, 90.9% vs. 88.8%, P = .984). Three-year CFS was 90.0%. The median OS has not been reached.The XELOX-XRT regimen is safe, with promising efficacy, and should be explored in larger trials for the treatment of locally advanced SCCA." @default.
• W2955480419 created "2019-07-12" @default.
• W2955480419 creator A5006330859 @default.
• W2955480419 creator A5009132832 @default.
• W2955480419 creator A5016694714 @default.
• W2955480419 creator A5022898855 @default.
• W2955480419 creator A5034037126 @default.
• W2955480419 creator A5035371911 @default.
• W2955480419 creator A5044974761 @default.
• W2955480419 creator A5050429899 @default.
• W2955480419 creator A5078928605 @default.
• W2955480419 creator A5080692116 @default.
• W2955480419 creator A5082668053 @default.
• W2955480419 creator A5088821817 @default.
• W2955480419 date "2019-12-01" @default.
• W2955480419 modified "2023-10-01" @default.
• W2955480419 title "A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal" @default.
• W2955480419 cites W1804130247 @default.
• W2955480419 cites W1910716144 @default.
• W2955480419 cites W1985456066 @default.
• W2955480419 cites W2004367809 @default.
• W2955480419 cites W2007296899 @default.
• W2955480419 cites W2008750108 @default.
• W2955480419 cites W2020355167 @default.
• W2955480419 cites W2051941210 @default.
• W2955480419 cites W2055442814 @default.
• W2955480419 cites W2062681066 @default.
• W2955480419 cites W2094501197 @default.
• W2955480419 cites W2096296732 @default.
• W2955480419 cites W2097158913 @default.
• W2955480419 cites W2100671482 @default.
• W2955480419 cites W2108051921 @default.
• W2955480419 cites W2119237890 @default.
• W2955480419 cites W2123712900 @default.
• W2955480419 cites W2124675713 @default.
• W2955480419 cites W2128328462 @default.
• W2955480419 cites W2130647939 @default.
• W2955480419 cites W2146269511 @default.
• W2955480419 cites W2151253787 @default.
• W2955480419 cites W2156409369 @default.
• W2955480419 cites W2158244375 @default.
• W2955480419 cites W2164644812 @default.
• W2955480419 cites W2229547569 @default.
• W2955480419 cites W2492618519 @default.
• W2955480419 cites W2565526207 @default.
• W2955480419 cites W2579647781 @default.
• W2955480419 cites W2587723909 @default.
• W2955480419 cites W2599261073 @default.
• W2955480419 cites W2781525129 @default.
• W2955480419 cites W2795004907 @default.
• W2955480419 cites W2800179148 @default.
• W2955480419 cites W4362207802 @default.
• W2955480419 doi "https://doi.org/10.1016/j.clcc.2019.06.003" @default.
• W2955480419 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31350201" @default.
• W2955480419 hasPublicationYear "2019" @default.
• W2955480419 type Work @default.
• W2955480419 sameAs 2955480419 @default.
• W2955480419 citedByCount "7" @default.
• W2955480419 countsByYear W29554804192021 @default.
• W2955480419 countsByYear W29554804192022 @default.
• W2955480419 countsByYear W29554804192023 @default.
• W2955480419 crossrefType "journal-article" @default.
• W2955480419 hasAuthorship W2955480419A5006330859 @default.
• W2955480419 hasAuthorship W2955480419A5009132832 @default.
• W2955480419 hasAuthorship W2955480419A5016694714 @default.
• W2955480419 hasAuthorship W2955480419A5022898855 @default.
• W2955480419 hasAuthorship W2955480419A5034037126 @default.
• W2955480419 hasAuthorship W2955480419A5035371911 @default.
• W2955480419 hasAuthorship W2955480419A5044974761 @default.
• W2955480419 hasAuthorship W2955480419A5050429899 @default.
• W2955480419 hasAuthorship W2955480419A5078928605 @default.
• W2955480419 hasAuthorship W2955480419A5080692116 @default.
• W2955480419 hasAuthorship W2955480419A5082668053 @default.
• W2955480419 hasAuthorship W2955480419A5088821817 @default.
• W2955480419 hasConcept C121608353 @default.
• W2955480419 hasConcept C126322002 @default.
• W2955480419 hasConcept C141071460 @default.
• W2955480419 hasConcept C143998085 @default.
• W2955480419 hasConcept C2776694085 @default.
• W2955480419 hasConcept C2777909004 @default.
• W2955480419 hasConcept C2779840525 @default.
• W2955480419 hasConcept C2780035688 @default.
• W2955480419 hasConcept C2780456651 @default.
• W2955480419 hasConcept C2780962732 @default.
• W2955480419 hasConcept C2781074409 @default.
• W2955480419 hasConcept C2781413609 @default.
• W2955480419 hasConcept C31760486 @default.
• W2955480419 hasConcept C509974204 @default.
• W2955480419 hasConcept C526805850 @default.
• W2955480419 hasConcept C71924100 @default.
• W2955480419 hasConcept C90924648 @default.
• W2955480419 hasConceptScore W2955480419C121608353 @default.
• W2955480419 hasConceptScore W2955480419C126322002 @default.
• W2955480419 hasConceptScore W2955480419C141071460 @default.
• W2955480419 hasConceptScore W2955480419C143998085 @default.
• W2955480419 hasConceptScore W2955480419C2776694085 @default.
• W2955480419 hasConceptScore W2955480419C2777909004 @default.
• W2955480419 hasConceptScore W2955480419C2779840525 @default.

• next